Skip to main content
logo
Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
28.51
-0.92 (-3.13%)
At close: Sep 28, 2026, 4:00 PM EDT
29.14
+0.63 (2.21%)
Pre-market: Sep 29, 2026, 8:46 AM EDT

Adaptive Biotechnologies Operating Metrics

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Number of Clonoseq Tests Delivered
125.86K115.07K105.59K96.49K88.98K82.18K76.11K70.84KUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Number of Clonoseq Tests Delivered Growth
41.44%40.01%38.74%36.21%34.19%33.72%34.71%37.98%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Revenue by Segment

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
MRD
251.94M235.71M212.33M190.60M171.28M156.62M145.53M136.14MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
MRD Growth
47.09%50.49%45.90%40.00%38.87%37.46%41.65%36.03%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Immune Medicine
56.15M59.70M64.64M62.16M33.94M32.90M33.43M41.14MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Immune Medicine Growth
65.43%81.45%93.38%51.09%-25.29%-45.67%-50.50%-48.32%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Immune Medicine Revenue Breakdown

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
Collaboration
33.74M37.68M41.28M44.78M14.55M12.36M13.45M17.87MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Collaboration Growth
131.97%204.77%206.88%150.58%-34.98%-67.59%-68.41%-64.93%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Immune Medicine Service
22.40M22.02M23.36M17.38M19.39M20.54M19.98M23.27MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Immune Medicine Service Growth
15.53%7.21%16.94%-25.31%-15.89%-8.37%-19.96%-18.79%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Adjusted EBITDA by Segment

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024
MRD
38.64M31.44M15.19M-1.79M-14.87M-28.08M-41.22M
Immune
4.04M4.24M9.16M5.36M-23.56M-24.52M-26.01M

MRD Revenue Breakdown

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
Service
233.44M211.71M192.83M174.10M156.28M144.12M133.03M123.64MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Service Growth
49.37%46.89%44.96%40.81%34.91%31.69%29.48%26.06%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Regulatory Milestone
18.50M24.00M19.50M16.50M15.00M12.50M12.50M12.50MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Regulatory Milestone Growth
23.33%92.00%56.00%32.00%100.00%177.78%-525.00%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade